全文获取类型
收费全文 | 5252篇 |
免费 | 364篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 117篇 |
妇产科学 | 136篇 |
基础医学 | 824篇 |
口腔科学 | 93篇 |
临床医学 | 444篇 |
内科学 | 1333篇 |
皮肤病学 | 90篇 |
神经病学 | 626篇 |
特种医学 | 119篇 |
外科学 | 505篇 |
综合类 | 8篇 |
一般理论 | 3篇 |
预防医学 | 311篇 |
眼科学 | 78篇 |
药学 | 438篇 |
中国医学 | 9篇 |
肿瘤学 | 474篇 |
出版年
2024年 | 5篇 |
2023年 | 53篇 |
2022年 | 119篇 |
2021年 | 181篇 |
2020年 | 111篇 |
2019年 | 149篇 |
2018年 | 155篇 |
2017年 | 115篇 |
2016年 | 168篇 |
2015年 | 167篇 |
2014年 | 197篇 |
2013年 | 288篇 |
2012年 | 407篇 |
2011年 | 401篇 |
2010年 | 234篇 |
2009年 | 201篇 |
2008年 | 367篇 |
2007年 | 369篇 |
2006年 | 305篇 |
2005年 | 343篇 |
2004年 | 326篇 |
2003年 | 275篇 |
2002年 | 258篇 |
2001年 | 38篇 |
2000年 | 24篇 |
1999年 | 32篇 |
1998年 | 44篇 |
1997年 | 49篇 |
1996年 | 30篇 |
1995年 | 41篇 |
1994年 | 26篇 |
1993年 | 15篇 |
1992年 | 20篇 |
1991年 | 17篇 |
1990年 | 10篇 |
1989年 | 15篇 |
1988年 | 12篇 |
1987年 | 13篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1976年 | 4篇 |
1969年 | 3篇 |
1968年 | 3篇 |
1966年 | 4篇 |
排序方式: 共有5662条查询结果,搜索用时 13 毫秒
51.
Eman Abu-Gharbieh Valentina Vasina Elisabetta Poluzzi Fabrizio De Ponti 《Pharmacological research》2004,50(3):211-222
Macrolides are widely used antibacterial agents. Although generally well tolerated, they have a number of important additional pharmacological effects, which can sometimes result in significant adverse reactions. This review focuses on three of these side effects: the prokinetic action associated with stimulation of motilin receptors, the proarrhythmic effect due to prolongation of the QT interval of the electrocardiogram and the potential for drug interactions due to inhibition of drug metabolising enzymes. For macrolides that have obtained marketing authorisation in Italy, United Kingdom or United States of America, we also considered whether these actions are properly reported in the approved summaries of the product characteristics and tried to provide strategies to identify patients at risk of significant side effects when macrolides are administered. 相似文献
52.
Lorenzo Fornaro Gianna Musettini Paola Orlandi Irene Pecora Caterina Vivaldi Marta Banchi Francesca Salani Elisabetta Fini Valentina Massa Silvia Catanese Federico Cucchiara Monica Lencioni Gianluca Masi Enrico Vasile Guido Bocci 《American journal of cancer research》2022,12(7):3347
Ramucirumab plus paclitaxel is considered the standard of care in the second-line treatment of gastric carcinoma (GC). The aim of this study was to evaluate plasma vascular endothelial growth factor-A (VEGF-A), VEGF-D, and circulating soluble VEGF receptor-2 (sVEGFR-2) as possible markers of resistance or response to ramucirumab administered with paclitaxel in pretreated metastatic GC patients. Plasma samples were collected at different time points (on days 1 and 15 of the first 3 cycles, at best radiologic response and at disease progression). VEGF-A, VEGF-D and sVEGFR-2 were analysed by ELISA. Correlations of biomarker baseline levels or dynamic changes with outcome measures were assessed. Progression-free survival (PFS) was the primary endpoint of the study. Forty-one patients were enrolled. VEGF-A and VEGF-D, but not sVEGFR-2, values significantly increased during treatment compared to baseline (P < 0.001). A positive correlation between VEGF-A and sVEGFR-2 at cycle 2 was found (P=0.045). At univariate analysis, higher baseline levels of VEGF-A were associated with worse OS (P=0.015). Early increase of sVEGFR-2 levels after the first treatment cycle was the only factor associated with longer PFS (6.6 vs. 3.6 months, P=0.049) and OS (18.6 vs. 5.2 months, P=0.008). Significance of sVEGFR-2 early increase was retained at multivariate analysis for OS (HR 0.32; 95% CI 0.12-0.91; P=0.032). The reported results confirmed the prognostic role of baseline VEGF-A and, with the limitations of the limited sample size and the lack of a control arm, suggested that the early increase of sVEGFR-2 after 1 cycle of treatment could be a potential predictive biomarker of benefit from second-line ramucirumab plus paclitaxel in GC. 相似文献
53.
Silvia Bianchi Maria Gori Clara Fappani Giulia Ciceri Marta Canuti Daniela Colzani Marco Dura Mara Terraneo Anna Lamberti Melissa Baggieri Sabrina Senatore Marino Faccini Fabio Magurano Elisabetta Tanzi Antonella Amendola 《Viruses》2022,14(5)
Despite the existence of an effective live-attenuated vaccine, measles can appear in vaccinated individuals. We investigated breakthrough measles cases identified during our surveillance activities within the measles/rubella surveillance network (MoRoNet) in Milan and surrounding areas (Northern Italy). Between 2017 and 2021, we confirmed measles virus (genotypes B3 or D8) infections in 653 patients and 51 of these (7.8%) were vaccinees. Among vaccinated individuals whose serum was available, a secondary failure was evidenced in 69.4% (25/36) of cases while 11 patients (30.6%) were non-responders. Non-responders were more frequently hospitalized and had significantly lower Ct values in both respiratory and urine samples. Median age and time since the last immunization were similar in the two groups. Importantly, we identified onward transmissions from vaccine failure cases. Vaccinees were involved in 20 outbreaks, in 10 of them they were able to transmit the virus, and in 8 of them, they were the index case. Comparing viral hemagglutinin sequences from vaccinated and non-vaccinated subjects did not show a specific mutation pattern. These results suggest that vaccination failure was likely due to the poor immune response of single individuals and highlights the importance of identifying breakthrough cases and characterizing their clinical and virologic profiles. 相似文献
54.
Metformin Decreases Circulating Androgen and Estrogen Levels in Nondiabetic Women With Breast Cancer
Carlo Campagnoli Franco Berrino Elisabetta Venturelli Chiara Abbà Nicoletta Biglia Tiziana Brucato Patrizia Cogliati Saverio Danese Michela Donadio Gianna Zito Patrizia Pasanisi 《Clinical breast cancer》2013,13(6):433-438
IntroductionDiabetic patients treated with metformin have a lower risk of developing BC or a better BC prognosis. Metformin might reduce cancer growth through direct antiproliferative effects or through indirect mechanisms, particularly the reduction of insulin. In a randomized study on nondiabetic BC patients in natural menopause with high testosterone levels, we observed a significant decrease in insulin and in testosterone levels with metformin 1500 mg/d compared with 1000 mg/d. We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones.Patients and MethodsOne hundred twenty-four eligible women were initially invited to take metformin 500 mg/d for 3 months. The 108 women who completed the first 3 months continued the study using 1000 mg/d for 1 month. The women were then randomized into 2 groups, and, for the subsequent 5 months, 1 group increased the dose to 1500 mg/d, and the other group continued with 1000 mg/d.ResultsNinety-six women completed the study, 43 receiving metformin 1500 mg/day, and 53 receiving 1000 mg/day. The women receiving 1500 mg/d showed a greater and significant reduction of free testosterone (?29%) and estradiol (?38%), a borderline significant reduction of estrone and insulin-like growth factor-1, and a nonsignificant reduction of androstenedione. They also showed a nonsignificant increase of dehydroepiandrosterone sulfate.ConclusionMetformin does not interfere with the production of dehydroepiandrosterone sulfate. Besides, it decreases estradiol levels, basically through the reduction of testosterone. These hormonal changes might have clinical relevance. 相似文献
55.
Lambertini E Piva R Khan MT Lampronti I Bianchi N Borgatti M Gambari R 《International journal of oncology》2004,24(2):419-423
56.
57.
58.
59.
60.
Eleonora Loi Cesare Zavattari Alessandro Tommasi Loredana Moi Matteo Canale Agnese Po Claudia Sabato Ana Florencia Vega-Benedetti Pina Ziranu Marco Puzzoni Eleonora Lai Luca Faloppi María Rulln Juan Carrascosa Irene Amat Jesús M. Urman Maria Arechederra Carmen Berasain Elisabetta Ferretti Andrea Casadei-Gardini Matías A. Avila Sergio Alonso Mario Scartozzi Patrizia Zavattari 《British journal of cancer》2022,126(12):1783
Background Biliary tract cancers (BTC) are rare but highly aggressive tumours with poor prognosis, usually detected at advanced stages. Herein, we aimed at identifying BTC-specific DNA methylation alterations.Methods Study design included statistical power and sample size estimation. A genome-wide methylation study of an explorative cohort (50 BTC and ten matched non-tumoral tissue samples) has been performed. BTC-specific altered CpG islands were validated in over 180 samples (174 BTCs and 13 non-tumoral controls). The final biomarkers, selected by a machine-learning approach, were validated in independent tissue (18 BTCs, 14 matched non-tumoral samples) and bile (24 BTCs, five non-tumoral samples) replication series, using droplet digital PCR.Results We identified and successfully validated BTC-specific DNA methylation alterations in over 200 BTC samples. The two-biomarker panel, selected by an in-house algorithm, showed an AUC > 0.97. The best-performing biomarker (chr2:176993479-176995557), associated with HOXD8, a pivotal gene in cancer-related pathways, achieved 100% sensitivity and specificity in a new series of tissue and bile samples.Conclusions We identified a novel fully efficient BTC biomarker, associated with HOXD8 gene, detectable both in tissue and bile by a standardised assay ready-to-use in clinical trials also including samples from non-invasive matrices.Subject terms: Diagnostic markers, Biliary tract cancer 相似文献